journal
MENU ▼
Read by QxMD icon Read
search

Seminars in Nuclear Medicine

journal
https://www.readbyqxmd.com/read/27987561/imaging-in-central-nervous-system-drug-discovery
#1
REVIEW
Roger N Gunn, Eugenii A Rabiner
The discovery and development of central nervous system (CNS) drugs is an extremely challenging process requiring large resources, timelines, and associated costs. The high risk of failure leads to high levels of risk. Over the past couple of decades PET imaging has become a central component of the CNS drug-development process, enabling decision-making in phase I studies, where early discharge of risk provides increased confidence to progress a candidate to more costly later phase testing at the right dose level or alternatively to kill a compound through failure to meet key criteria...
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27987560/a%C3%AE-amyloid-and-tau-imaging-in-dementia
#2
REVIEW
Victor L Villemagne, Vincent Doré, Pierrick Bourgeat, Samantha C Burnham, Simon Laws, Olivier Salvado, Colin L Masters, Christopher C Rowe
The introduction of in vivo imaging of Aβ-amyloid (Αβ) pathology more than a decade ago, transformed the assessment of Alzheimer disease (AD) allowing the evaluation of Aβ deposition over time by providing highly accurate, reliable, and reproducible quantitative statements of regional or global Aβ burden in the brain to the extent that Aβ imaging has already been approved for clinical use and is being used for both patient recruitment and outcome measure in current anti-Αβ therapeutic trials. Aβ imaging studies have deepened our insight into Aβ deposition, showing that Aβ accumulation is a slow and protracted process extending for more than two decades before the onset of the clinical phenotype...
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27987559/blunted-dopamine-transmission-in-addiction-potential-mechanisms-and-implications-for-behavior
#3
REVIEW
Pierre Trifilieff, Fabien Ducrocq, Suzanne van der Veldt, Diana Martinez
Positron emission tomography (PET) imaging consistently shows blunted striatal dopamine release and decreased dopamine D2 receptor availability in addiction. Here, we review the preclinical and clinical studies indicating that this neurobiological phenotype is likely to be both a consequence of chronic drug consumption and a vulnerability factor in the development of addiction. We propose that, behaviorally, blunted striatal dopamine transmission could reflect the increased impulsivity and altered cost/benefit computations that are associated with addiction...
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27987558/recent-developments-in-molecular-brain-imaging-of-neuropsychiatric-disorders
#4
REVIEW
Mark Slifstein, Anissa Abi-Dargham
Molecular imaging with PET or SPECT has been an important research tool in psychiatry for as long as these modalities have been available. Here, we discuss two areas of neuroimaging relevant to current psychiatry research. The first is the use of imaging to study neurotransmission. We discuss the use of pharmacologic probes to induce changes in levels of neurotransmitters that can be inferred through their effects on outcome measures of imaging experiments, from their historical origins focusing on dopamine transmission through recent developments involving serotonin, GABA, and glutamate...
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27987557/brain-tumors-an-update-on-clinical-pet-research-in-gliomas
#5
REVIEW
Karl Herholz
A previous review published in 2012 demonstrated the role of clinical PET for diagnosis and management of brain tumors using mainly FDG, amino acid tracers, and (18)F-fluorothymidine. This review provides an update on clinical PET studies, most of which are motivated by prediction of prognosis and planning and monitoring of therapy in gliomas. For FDG, there has been additional evidence supporting late scanning, and combination with (13)N ammonia has yielded some promising results. Large neutral amino acid tracers have found widespread applications mostly based on (18)F-labeled compounds fluoroethyltyrosine and fluorodopa for targeting biopsies, therapy planning and monitoring, and as outcome markers in clinical trials...
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27987556/presurgical-focus-localization-in-epilepsy-pet-and-spect
#6
REVIEW
William H Theodore
Positron emission tomography (PET) and single photon emission computed tomography (SPECT) can be used to assist localization of seizure foci in patients with drug-resistant epilepsy. Both should be interpreted in the context of clinical, electrographic, and magnetic resonance imaging data. PET has wider research applications, particularity when used with ligands for neurotransmitter receptors or inflammatory processes.
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27987555/clinical-amyloid-imaging
#7
REVIEW
Atul Mallik, Alex Drzezga, Satoshi Minoshima
Amyloid plaques, along with neurofibrillary tangles, are a neuropathologic hallmark of Alzheimer disease (AD). Recently, amyloid PET radiotracers have been developed and approved for clinical use in the evaluation of suspected neurodegenerative disorders. In both research and clinical settings, amyloid PET imaging has provided important diagnostic and prognostic information for the management of patients with possible AD, mild cognitive impairment (MCI), and other challenging diagnostic presentations. Although the overall impact of amyloid imaging is still being evaluated, the Society of Nuclear Medicine and Molecular Imaging and Alzheimer's Association Amyloid Imaging Task Force have created appropriate use criteria for the standard clinical use of amyloid PET imaging...
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27987554/updates-in-molecular-brain-imaging
#8
EDITORIAL
Kirk A Frey
No abstract text is available yet for this article.
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27987553/molecular-imaging-of-extrapyramidal-movement-disorders
#9
REVIEW
Kirk A Frey
Extrapyramidal movement disorders including Parkinson disease, multiple systems atrophy, progressive supranuclear palsy, and corticobasal degeneration are neurodegenerative syndromes with distinct neuropathological changes, indicating differing underlying etiologies. Clinical features that may distinguish among these conditions are often absent, particularly early after the onset of symptoms. Therapy is presently limited, and there are no established disease-modifying or neuroprotective interventions. Advances in therapeutics will depend on the early and accurate diagnostic classification of patients...
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27987552/letter-from-the-editors
#10
EDITORIAL
Leonard M Freeman, M Donald Blaufox
No abstract text is available yet for this article.
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27825434/radium-223-therapy-of-bone-metastases-in-prostate-cancer
#11
REVIEW
Sten Nilsson
Metastatic castration-resistant prostate cancer frequently metastasizes to the bone, often resulting in painful skeletal events, reduced quality of life, and reduced survival. Radium-223 is a first-in-class alpha-emitting radiopharmaceutical that has proven to prolong overall survival, delay time to symptomatic skeletal events, and improve quality of life in patients with castration-resistant prostate cancer and symptomatic bone metastases and no visceral metastases. Radium-223 provides survival benefit to patients with castration-resistant prostate cancer and symptomatic bone metastases, regardless of prior docetaxel use...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27825433/advancement-of-mr-and-pet-mr-in-prostate-cancer
#12
REVIEW
Liza Lindenberg, Mark Ahlman, Baris Turkbey, Esther Mena, Peter Choyke
Multiparametric magnetic resonance (mpMRI) imaging has assumed a larger role in the diagnosis and management of prostate cancer. The current method of detecting prostate cancer relies on blind systematic biopsy, guided only by transrectal ultrasound that generally directs the needle biopsy to sextants of the prostate rather than specific lesions. MpMRI is playing an increasing role in the detection of primary cancer as it can visualize cancers and direct biopsies. However, even mpMRI is inherently nonspecific and numerous biopsies performed under MR guidance prove to be negative...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27825432/psma-pet-and-radionuclide-therapy-in-prostate-cancer
#13
REVIEW
Kirsten Bouchelouche, Baris Turkbey, Peter L Choyke
Prostate cancer (PCa) is the most common malignancy in men and a major cause of cancer death. Accurate imaging plays an important role in diagnosis, staging, restaging, detection of biochemical recurrence, and for therapy of patients with PCa. Because no effective treatment is available for advanced PCa, there is an urgent need to develop new and more effective therapeutic strategies. To optimize treatment outcome, especially in high-risk patients with PCa, therapy for PCa is moving rapidly toward personalization...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27825431/pet-tracers-beyond-fdg-in-prostate-cancer
#14
REVIEW
David M Schuster, Cristina Nanni, Stefano Fanti
Conventional anatomical imaging with CT and MRI has limitations in the evaluation of prostate cancer. PET is a powerful imaging technique, which can be directed toward molecular targets as diverse as glucose metabolism, density of prostate-specific membrane antigen receptors, and skeletal osteoblastic activity. Although 2-deoxy-2-(18)F-FDG-PET is the mainstay of molecular imaging, FDG has limitations in typically indolent prostate cancer. Yet, there are many useful and emerging PET tracers beyond FDG, which provide added value...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27825430/is-there-use-for-fdg-pet-in-prostate-cancer
#15
REVIEW
Hossein Jadvar
The use of positron emission tomography (PET) with (18)F-fluorodeoxyglucose (FDG) in prostate cancer depends on the phase of the disease along the natural history of this prevalent malignancy in men. Incidental high FDG uptake in the prostate gland, although rare, should prompt further investigation with at least a measurement of serum prostate specific antigen level. Although in general FDG uptake level may significantly overlap among normal, benign, and malignant tissues, aggressive primary tumors with Gleason score > 7 tend to display high FDG uptake...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27825429/-18-f-naf-pet-ct-and-99m-tc-mdp-bone-scintigraphy-in-the-detection-of-bone-metastases-in-prostate-cancer
#16
REVIEW
Werner Langsteger, Alireza Rezaee, Christian Pirich, Mohsen Beheshti
(99m)Tc-MDP whole-body bone scintigraphy is a highly sensitive imaging method that has been used for decades to evaluate prostate cancer bone metastasis based on its availability and low cost; however, because of accumulation of this radiotracer in degenerative, traumatic, and inflammatory lesions, it suffers from noncomparable specificity. The modality is also used to monitor response to therapy and to predict patients' prognosis. As planar imaging may not give enough information for lesion detection or anatomical localization, it can be supplemented with SPECT to increase image contrast particularly in the evaluation of small and complex skeleton...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27825428/diagnostic-and-therapeutic-strategies-for-prostate-cancer
#17
REVIEW
Mary Nguyen-Nielsen, Michael Borre
Prostate cancer (PC) is a major disease that affects men's health worldwide. It is the second most common form of cancer in men, surpassed only by nonmelanoma skin cancers such as basal and squamous cell carcinomas. Diagnostic strategies with population screening for prostate cancer using prostate-specific antigen (PSA) has been surrounded with controversy and debated intensively ever since the PSA protein was first purified in 1979 by Wang et al. At the same time, advances in diagnostic imaging, surgery, radiation, and chemotherapy have increased the opportunity to effectively diagnose, treat, and manage PC...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27825427/guest-editorial-prostate-cancer
#18
EDITORIAL
Kirsten Bouchelouche
No abstract text is available yet for this article.
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27825426/erratum-to-evaluation-of-osseous-metastasis-in-bone-scintigraphy-semin-nucl-med-46-2016-340-358
#19
Amir Reza Jalilian, Davood Beiki, Arman Hassanzadeh-Rad, Arash Eftekhari, Parham Geramifar, Mohammad Eftekhari
No abstract text is available yet for this article.
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27825425/letter-from-the-editors
#20
EDITORIAL
Leonard M Freeman, M Donald Blaufox
No abstract text is available yet for this article.
November 2016: Seminars in Nuclear Medicine
journal
journal
20239
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"